Real World Patient-Reported Outcomes in Chinese Her2+ EBC Patients Receiving (Neo) Adjuvant Anti-Her2 Based Therapy
Status: RECRUITING
Study type: OBSERVATIONAL
Conditions: HER2-positive Breast Cancer
Sponsor: Fudan University